Objectives: Therapeutic hypothermia TH became broadly used in the management of the asphyxiated newborns. Although two cooling methods are used, so far the superiority of none of them has been established. The purpose of the study is to compare two cooling methods: selective head cooling (SHC) and whole body cooling (WBC) Material and methods:We conducted a prospective observational study in newborns with HIE. The patients received one of methods: SHC or WBC. The eligibility criteria were similar to previous studies. Stability of cardio-respiratory parameters and short term outcomes were analyzed.Results: 78 neonates with hypoxic-ischemic encephalopathy due to perinatal asphyxia were involved in this study. The SHC group consisted of 51 newborns, the WBC group consisted of 27 patients. Both study groups had similar baseline characteristics and condition at birth. There were no significant differences in hospital course, neurological status and adverse effects associated with cooling procedure between groups. Analyzing the rate of thrombocytopenia and the number of transfusions of blood components no statistically significant differences were found between the groups. Conclusions:Results of our study indicate that two compared methods of TH despite varied target core temperature ranges do not differ significantly according to clinical course and risk of adverse events. Further observations are conducted and we look forward to the results of the long neurodevelopmental care.

Background-Posterior urethral valves (PUV) accounts for 17% of pediatric renal failure. The management of pregnancies involving fetuses with PUV is hampered by the fact that current clinical parameters obtained from fetal ultrasound and/or fetal urine biochemistry are insufficient to predict postnatal renal function. We previously have developed a fetal urine peptide signature (12PUV) that predicted with high precision postnatal renal failure at 2 years of age in fetuses with PUV. Here we evaluated the accuracy of this signature to predict postnatal renal outcome in fetuses with PUV in an independent single center study. Methods-Thirty three woman carrying fetuses with suspected PUV were included. Twenty five fetuses received vesicoamniotic shunts (VAS) during pregnancy. PUV was confirmed postnatally in 23 patients. Of those 23 fetuses, 2 were lost in follow-up. Four and 3 patients died in the pre-and perinatal-period, respectively. Follow-up renal function at 6 month of age was obtained for the remaining 14 patients. The primary outcome was early renal failure, defined by an eGFR<60 mL/min/1.73 before 6 months of age or pre-or perinatal death. Results-The peptide signature predicted postnatal renal outcome in postnatally confirmed PUV fetuses with an AUC of 0.94 (95%CI: 0.74-1.0) and an accuracy of 90% (95%CI: 78-100). The signature predicted postnatal renal outcome for the suspected PUV cases with an AUC of 0.89 (95%CI: 0.72-0.97) and an accuracy of 84% (95%CI: 71-97). Conclusion-This single center study confirms the predictive power of the previously identified 12PUV fetal urinary peptide signature.

No abstract

No abstract

No abstract